Skip to main content
. 2013 Apr 12;4:19. doi: 10.3389/fendo.2013.00019

Table 2.

PROKR2 and PROK2 mutations in Kallmann syndrome.

Exon Nucleotide change Amino acid change Localization (domain) Functional consequence Reference
PROKR2
1 58del Frameshift N-terminal region NMD or protein truncation Dodé et al. (2006)
151G > A A51T N-terminal region None? Reynaud et al. (2012), Sbai et al. (unpublished)
238C > T R80C First intracellular loop None? Abreu et al. (2010), Sbai et al. (unpublished)
253C > T R85C Mild G protein-coupling defect Cole et al. (2008), Monnier et al. (2009), Sarfati et al. (2010)
253C > G R85G Strong G protein-coupling defect Sarfati et al. (2010), Raivio et al. (2012)
254G > T R85L Mild protein-coupling defect Sarfati et al. (2010), Sbai et al. (unpublished)
254G > A R85H Mild G protein-coupling defect Dodé et al. (2006), Monnier et al. (2009)
337T > C Y113H First extracellular loop Strong G protein-coupling defect Cole et al. (2008), Sbai et al. (unpublished)
343G > A V115M Strong G protein-coupling defect Cole et al. (2008), Sbai et al. (unpublished)
349C > T R117W Strong G protein-coupling defect Sbai et al. (unpublished)
420C > G Y140X Third transmembrane domain NMD or protein truncation Abreu et al. (2010)
2 491G > A R164Q Second intracellular loop Mild G protein-coupling defect Dodé et al. (2006), Cole et al. (2008), Monnier et al. (2009)
518T > G L173R Fourth transmembrane domain Cell surface-targeting defect Dodé et al. (2006), Abreu et al. (2010), Cole et al. (2008), Monnier et al. (2009)
533G > C W178S Cell surface-targeting defect Dodé et al. (2006), Cole et al. (2008), Monnier et al. (2009)
563C > T S188L Strong G protein-coupling defect Cole et al. (2008), Sbai et al. (unpublished)
604A > G S202G Second extracellular loop ? Chan et al. (2009)
629A > G Q210R Ligand-binding defect Dodé et al. (2006), Monnier et al. (2009)
701G > A G234D Fifth transmembrane domain Cell surface-targeting defect Sbai et al. (unpublished)
743G > A R248Q Third intracellular loop None? Cole et al. (2008)
752G > T W251L Strong G protein-coupling defect? Sarfati et al. (2010), Sbai et al. (unpublished)
802C > T R268C G protein-coupling defect? Dodé et al. (2006), Abreu et al. (2010), Monnier et al. (2009), Sarfati et al. (2010)
T820 > A V274D Sixth transmembrane domain Strong G protein-coupling defect Sinisi et al. (2008), Sbai et al. (unpublished)
868C > T P290S Cell surface-targeting defect Dodé et al. (2006), Monnier et al. (2009)
969G > A M323I Seventh transmembrane domain None? Dodé et al. (2006), Monnier et al. (2009)
989del Frameshift NMD or protein truncation Sarfati et al. (2010)
991G > A V331M Mild G protein-coupling defect Dodé et al. (2006), Cole et al. (2008), Monnier et al. (2009), Sarfati et al. (2010)
1069C > T R357W C-terminal region None? Cole et al. (2008), Sbai et al. (unpublished)
PROK2
1 −4C > A Translation initiation site Reduced protein synthesis? Dodé et al. (2006)
70G > C A24P Signal peptide ? Cole et al. (2008)
94G > C G32R AVITGA motif Strongly impaired activity? Dodé et al. (2006)
2 101 G > A C34Y Cysteine-rich region Strongly impaired activity Cole et al. (2008)
137G > A C46Y Cysteine-rich region ? Dodé et al. (unpublished)
150C > G I50M None? Cole et al. (2008)
161G > A S54N ? Sarfati et al. (2010)
163del Frameshift NMD or protein truncation Pitteloud et al. (2007), Leroy et al. (2008)
217C > T R73C Strongly impaired activity Dodé et al. (2006), Leroy et al. (2008), Cole et al. (2008)
4 297_298insT Frameshift NMD or protein truncation Dodé et al. (2006), Abreu et al. (2010)
301C > T R101W ? Dodé et al. (unpublished)
302G > A R101Q ? Dodé et al. (unpublished)
310C > T H104Y ? Sarfati et al. (2010)

Mutations reported in PROKR2 and PROK2 are mainly missense mutations. In most patients, the mutations have been found in heterozygous state. The R85C, R85H, R164Q, L173R, and P290S PROKR2 mutations, as well as R73C, c.163del, and c.297_298insT PROK2 mutations have, however, been found both in heterozygous and homozygous (or compound heterozygous) states, which suggests that patients heterozygous for PROKR2 or PROK2 mutations carry additional mutations, presumably in other, as yet unidentified Kallmann syndrome genes in most cases. Notably, two such patients have the L173R mutation in PROKR2 together with S396L or R423X mutations in KAL1 (Dodé et al., 2006; Sarfati et al., 2010), another patient has the V115M mutation in PROKR2 together with the A24P mutation in PROK2 (Cole et al., 2008), and still another patient has the R85L mutation in PROKR2 together with a A604T mutation in FGFR1 (Sarfati et al., 2010). In addition, the patient who has the S202G mutation in PROKR2 also has I239T and R31C monoallelic mutations in FGFR1 and GNRH1, respectively (Chan et al., 2009). Finally, two patients who carry R268C and V331M mutations in PROKR2 also carry A189T and R240Q monoallelic mutations in KISS1R and GNRHR, respectively (Sarfati et al., 2010). Abbreviation: NMD, nonsense-mediated mRNA decay.

?, not known.